Therapeutic potential of anti-IL-1 agents in hidradenitis suppurativa

Therapeutic potential of anti-IL-1 agents in hidradenitis suppurativa. Several targeted agents are currently available or under investigation for the treatment of HS, investigating the potential benefits of blocking the IL-1 signaling pathway at various levels. IL-1 and IL-36, by binding their respective receptor complexes, are able to induce the expression of downstream genes, mostly transducing proinflammatory mediators. Two monoclonal antibodies canakinumab and lutikizumab primarily target IL-1β. MEDI8968 and anakinra exert their action by inhibiting the IL-1R1 receptor, thus preventing its activation by both IL-1α and IL-1β. Spesolimab and imsidolimab are two agents selectively targeting the IL-36 receptor. Lastly, zimlovisertib and KT-474 target IRAK4, thereby blocking the downstream inflammatory cascade. AMPs, antimicrobial peptides; CCL, chemokine (C-C motif) ligand; CD, cluster of differentiation; CXCL, chemokine (C-X-C motif) ligand; HLA-DR, human leucocyte antigen-DR isotype; IL, interleukin; IFN, interferon; IRAK, interleukin receptor-associated kinase; MYD, myeloid differentiation primary response 88; TNF, tumor necrosis factor; TRAF, tumor necrosis factor receptor-associated factor

Publication

Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa (2024) Laura Calabrese, et al. Biomolecules. 2024 Feb;14(2). Figure: F2. Homo sapiens

Disease mentions